Navigating FDA Review Times in a Shifting Political Landscape: What MedTech Companies and Investors Need to Know

The regulatory landscape for medical devices is a critical factor for companies navigating the path to market. Recently, there has been significant discussion around FDA review times, particularly in light of recent staffing reductions and broader government efficiency initiatives. After analyzing various factors and consulting with industry leaders, we believe there is reason for cautious optimism.